Cytokine Release Symptoms rather than Syndromes: A call for Granular Reporting of Cytokine Related Adverse Events in Clinical Trials [0.03%]
细胞因子释放症状而非细胞因子释放综合症——临床试验中细胞因子相关不良事件的精细报告呼吁
J-D Fumet,M Roulleaux Dugage,F-X Danlos et al.
J-D Fumet et al.
Background: T-cell redirecting therapies, notably CAR T-cells and bispecific antibodies, have revolutionized the treatment of hematologic malignancies. Their rapid expansion into solid tumors, alongside the emergence of n...
Long-term survival outcomes with immune checkpoint inhibition in PD-L1 low or intermediate expressing gastroesophageal adenocarcinoma [0.03%]
程序性死亡配体1低表达或中等表达胃食管腺癌免疫检查点抑制的长期生存结果
J J Zhao,F Pietrantonio
J J Zhao
OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast Cancer [0.03%]
OPTIMAL研究：一项口服紫杉醇(DHP107)对比静脉注射周剂紫杉醇治疗HER2阴性复发或转移性乳腺癌的III期多中心临床试验
B Xu,H Jeong,T Sun et al.
B Xu et al.
Background: Intravenous (IV) paclitaxel requires prolonged infusion and is associated with hypersensitivity reactions and peripheral neuropathy. This study evaluated the efficacy and safety of DHP107, a novel oral formula...
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies [0.03%]
MTAP缺失在由致癌基因驱动的非小细胞肺癌中频现，并可能使联合应用PRMT5抑制剂和靶向药物的治疗方案变得有效
M Aldea,S Lenahan,M-A Locquet et al.
M Aldea et al.
Background: Homozygous loss of MTAP (methylthioadenosine phosphorylase) occurs in approximately 15% of cancers and leads to partial PRMT5 inhibition, creating a selective vulnerability to PRMT5 inhibitors. The frequency a...
A confidence-based, artificial intelligence pathology model for diagnosis of intrahepatic cholangiocarcinoma [0.03%]
基于信心水平的人工智能诊断肝内胆管癌的病理模型
Y Cheng,N Azouzi,A Laurent-Bellue et al.
Y Cheng et al.
Background: Intrahepatic cholangiocarcinoma (ICCA) is a rare but highly lethal adenocarcinoma arising within the hepatic parenchyma. Diagnosis presents a significant clinical challenge as the histological features of ICCA...
Reply to Letter Re: PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM) [0.03%]
关于PET/CT引导的免疫检查点阻断及长期反应者多模式治疗后评估的回信：德国国家网络基因组医学肺癌项目中的转移性肺癌患者
N Frost,M Reck
N Frost
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial [0.03%]
纳武单抗联合伊匹单抗与索拉非尼作为晚期肾细胞癌一线治疗的对比：III期CheckMate 214研究的最终分析（EFFICACY AND SAFETY RESULTS）
T K Choueiri,L Albigès,D F McDermott et al.
T K Choueiri et al.
Background: Nivolumab plus ipilimumab (NIVO+IPI) demonstrated significant long-term survival and response benefits in patients with previously untreated advanced renal cell carcinoma (aRCC) in the phase III CheckMate 214 ...
Reply to Letter to the Editor: 'ALBAN (GETUG-AFU 37): a phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC)' by R. Contieri et al [0.03%]
ALBAN(GITUX-AFU 37):一项关于阿特珠单抗联合卡介苗(BCG)与单独使用BCG治疗高危、非肌层浸润性膀胱癌(NMIBC)患者的III期、随机、开放标签、国际多中心临床试验致编辑信的回信
M Rouprêt
M Rouprêt